SPH XingLing Technology Pharmaceutical

SPH XingLing Technology Pharmaceutical is a specialized subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd., focused on the modernization of traditional Chinese medicine through advanced extraction technologies. The company is a leader in the production of standardized Ginkgo biloba extracts, specifically the GBE50 formulation, which is widely utilized for treating cardiovascular and cerebrovascular disorders. Its operations encompass the entire value chain from botanical cultivation and extraction to the manufacturing of finished dosage forms like granules and tablets. SPH XingLing's products are integral to the parent company's portfolio in the geriatric and chronic disease therapeutic areas. The company maintains high quality standards through its GMP-certified facilities and continuous investment in R&D for natural medicine.